ANI Pharmaceuticals Inc. (ANIP) and Acceleron Pharma Inc. (NASDAQ:XLRN) Contrasting side by side

ANI Pharmaceuticals Inc. (NASDAQ:ANIP) and Acceleron Pharma Inc. (NASDAQ:XLRN), both competing one another are Biotechnology companies. We will compare their dividends, analyst recommendations, profitability, risk, institutional ownership, earnings and valuation.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
ANI Pharmaceuticals Inc. 72 3.72 N/A 1.15 73.62
Acceleron Pharma Inc. 43 64.36 N/A -2.76 0.00

Table 1 shows the gross revenue, earnings per share (EPS) and valuation for ANI Pharmaceuticals Inc. and Acceleron Pharma Inc.

Profitability

Table 2 shows us the return on equity, return on assets and net margins of both companies.

Net Margins Return on Equity Return on Assets
ANI Pharmaceuticals Inc. 0.00% 7% 3.1%
Acceleron Pharma Inc. 0.00% -35.9% -33.4%

Risk & Volatility

ANI Pharmaceuticals Inc. has a 2.16 beta, while its volatility is 116.00%, thus making it more volatile than Standard & Poor’s 500. Competitively, Acceleron Pharma Inc.’s beta is 1.16 which is 16.00% more volatile than Standard & Poor’s 500.

Liquidity

The Current Ratio of ANI Pharmaceuticals Inc. is 0.9 while its Quick Ratio stands at 0.7. The Current Ratio of rival Acceleron Pharma Inc. is 19.3 and its Quick Ratio is has 19.3. Acceleron Pharma Inc. is better equipped to clear short and long-term obligations than ANI Pharmaceuticals Inc.

Analyst Ratings

Recommendations and Ratings for ANI Pharmaceuticals Inc. and Acceleron Pharma Inc. can be find in next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
ANI Pharmaceuticals Inc. 0 0 0 0.00
Acceleron Pharma Inc. 0 2 1 2.33

ANI Pharmaceuticals Inc. has a 4.82% upside potential and a consensus price target of $73. Meanwhile, Acceleron Pharma Inc.’s consensus price target is $52.33, while its potential upside is 12.25%. The data from earlier shows that analysts view suggest that Acceleron Pharma Inc. seems more appealing than ANI Pharmaceuticals Inc.

Insider & Institutional Ownership

The shares of both ANI Pharmaceuticals Inc. and Acceleron Pharma Inc. are owned by institutional investors at 86.2% and 93.6% respectively. Insiders owned 3.3% of ANI Pharmaceuticals Inc. shares. Comparatively, 0.6% are Acceleron Pharma Inc.’s share owned by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
ANI Pharmaceuticals Inc. 1.72% 2.27% 20.43% 55.98% 25.49% 87.89%
Acceleron Pharma Inc. 2.78% 3.39% 9.2% 4.8% 4% 0.25%

For the past year ANI Pharmaceuticals Inc.’s stock price has bigger growth than Acceleron Pharma Inc.

Summary

On 6 of the 10 factors ANI Pharmaceuticals Inc. beats Acceleron Pharma Inc.

ANI Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States. It focuses on producing controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. The company offers Erythromycin Ethylsuccinate to treat infections; Esterified Estrogen with Methyltestosterone for treating vasomotor symptoms of menopause; Etodolac to treat pain caused by osteoarthritis, rheumatoid arthritis, and other conditions; Fenofibrate for treating hypercholesterolemia; Flecainide to treat arrhythmia; Fluvoxamine for treating obsessive-compulsive and social anxiety disorders; and Hydrocortisone Enema and Cortenema to treat ulcerative colitis. It also provides Hydrocortisone Rectal Cream to treat inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses; Lithium Carbonate ER and Lithobid for bipolar disorder; Mesalamine Enema to treat distal ulcerative colitis, proctosigmoiditis, or proctitis; Methazolamide to treat ocular conditions; and Metoclopramide and Reglan to treat gastroesophageal reflux. In addition, the company offers Nilutamide to treat metastatic prostate cancer; Nimodipine that reduces the ischemic deficits in patients with subarachnoid hemorrhage; Opium Tincture to treat diarrhea; Oxycodone capsules and oral solution for pain; Propafenone to treat arrhythmia; Propranolol ER and Inderal LA for managing hypertension in patients with angina pectoris; and Vancomycin and Vancocin for use in treating C. difficile-associated diarrhea and enterocolitis. Further, it provides contract manufacturing services for other pharmaceutical companies. The company markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. ANI Pharmaceuticals, Inc. is headquartered in Baudette, Minnesota.

Acceleron Pharma Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for serious and rare diseases. Its therapeutic candidates include luspatercept to treat anemia and associated complications in patients with myelodysplastic syndromes and beta-thalassemia; and sotatercept for chronic kidney diseases. The companyÂ’s therapeutic candidates also include dalantercept, a tyrosine kinase inhibitor, which is in phase II clinical trials for renal cell carcinoma; and ACE-083 that is in phase II clinical trials for facioscapulohumeral dystrophy. It has collaboration, license, and option agreement with Celgene Corporation. The company was formerly known as Phoenix Pharma, Inc. Acceleron Pharma Inc. was founded in 2003 and is headquartered in Cambridge, Massachusetts.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.